The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Hi Trek,
Thanks for the tip. I have not been using Google financial but rather my investment platforms to create watchlists (IG and HL). Will give Google a try.
To be honest the only Small Caps that I am currently in in this sector are Open Orphan, Destiny Pharma and Oncimmune. Otherwise most other Investments are in Tech, O&G and some others scattered around.
Different markets move differently based on a plethora of reasons e.g. O&G largely driven by Covid news/lockdowns and OPEC+ decisions and some other macro economics whilst tech is hyped up and largely driven by general economic data, supply chain- chip shortage and currently of course decisions the Fed makes. Whilst O&G can go down due to Covid it may be a boost for some tech I.e. in software.
Regardless, you would think that Covid/ Omicron would bode well for the types of services ONC and others provide in the sector. I can only attribute then the drop sector wide to be related to some recent decisions by BoE and Fed to teratively increase interest rates throughout 2022 and beyond and to curb the QE / bond buying. What I am noticing is that due to some uncertainty especially toward end of the year and into the holidays some investors might just want to pull out and wait until next quarter before they put their money down, in the hope there may be more clarity and business certainty.
The world is a mess.....but I suppose my dad would have said the same in the 70s./80s. Seems like stakes are just a bit higher now.
I'll put together a Google watch list. Sounds like I might be missing something in my toolbox.
Thanks.
Well I'd be a fool if I took a left turn. I ought to spend some time with the family and get them silently ready for the good times ahead. Thanks @Gilers1 @buffettt12 ... maybe we salute each other some years in the future in the metaverse and drink some expensive Scotch to celebrate not being a lightweight
I suppose the world decided that its no good to invest right now. What a tragedy. Maybe we are headed for a nuclear engagement with the Eastern powers and I am just the last one that got the memo. In any case. I will be there in 12 months...believe me....(I hope)
I can see how people get frustrated on this market here. There are big investors with lots of shares and it seems like a handful of other traders trying their luck with this great company + no liquidity When it seems like everyone should be buying, with news being fantastic and valuation estimates at 2.7x of what the price is now. The price declines as there is a big seller (seems to always be the case). An honest question here: Are we the Don Quixotes', sitting on a donkey and fighting a windmill?
I keep pumping and pumping but so far the red has only increased in the last 7 months. I would appreciate if anyone had a serious and plausible explanation. Patience is one answer that I am all in on. But I need to understand this better. Is is simples?
Since I like the idea of a company that saves lives but also in a legitimate way (metaphorically speaking) is a 'printing machine for cash', I just threw a bunch more money at it and bought at what you would think is a killer price of 157p. Now if all stories hold true...this should be a great decision. And as Trek would say "...usual caveats"...although there really shouldn't be many
Does anyone have a take on how the rising inflation particularly in the US (CPI 6.8% at present) and UK (CPI 3.6%) impacts a company like ONC? With such high margins and a product that relies less on material purchase and manufacturing but rather on studies, data and PII. When the Federal Reserve, BoE/ Central Banks raise the interest rates to counter inflation next year it will on one hand make debt more expensive and on the other strengthen certain currencies. I wonder how this will affect ONC and the wider supply chain from a commercial standpoint?!. It would be great if ONC was not too affected due to their high margin immunoinsights business, as well as the current valuation. The stock price is already showing huge upside potential but could hesitancy be a reason for the stalling prices The? The fact that the business has 85% margins means that they have enough room to manouver this macro economic issue. I would love to hear from the group on this topic. Could it be that some investors are currently just hesitant to put their money into high risk, low cap businesses like ONC? I say high risk only because it feels like another quarter /report is needed to prove the upward trend is legit (in numbers).
I am not here to badmouth anyone based on their opinions. But unfortunately Lightweight84 will be proven terribly wrong in the coming 3months. When the interim report comes out.
You will have seen a slowdown in business across many many sectors in the summer FY21. But it was clearly states that there has been tremendous uptick in demand in September. Of course US sales professionals with the required credentials come at a cost but they will carry multi mio. sales targets and with their experience and connection I am sure this product will sell and it will sell hard! The NHS deals will come...you know that NHS moves slow like an Oil tanker but they will eventually but once the commissions sign off. Flood gates will open. There are deals with pharma businesses around the world including. Germany which is arguable one of the more important and strategic markets for ONC.
It surprising that you are hung up on the company running out of cash.....what are you talking about? The company should be profitable in 1-2 years latest. I would recommend you put your money back into ONC right now... all of it!!! ..... or leave the board. No hard feelings but we are about to take off brother.
https://www.**********.co.uk/media/6187c293cfcda300170aa25f/?context=/listings/LON/ONC
This interview was conducted on 07.11.21 but still a shorter follow up to the FY21 report from last week. Worth listening into for anyone that has doubt.
It might take until next trading update (i estimate around end of Jan/Feb for half year results) for the share price to have its next bigger breakthrough.
I wouldn't want to make too many assumptions here either but I honestly don't see the value for Oncimmune to agree to a takeover. Of course they would have access to a larger set or financial and network resources but primarily it would be a a juicy payoff for all equity holders.
IThe company currently is at the beginning of its journey on a 'blank canvas' with little to no direct competitors in the immediate vicinity and they have a chance to build a true services business that transacts with all Pharma rather than integrate into a narrower network. No doubt will there be interest an offerings on the table soon if not already. But if this is truly a be dollar company in the making, the chance to be acquire will come around more than once. So why seel so early when you can ride the wave of expansion further and then sell at a much higher value.
Agreed and amen. The slowdown in commercial activity was felt across alot of other companies in this space and beyond over the summer. You got to let these guys crack on. HODL and keep buying in. I can only imagine that this coming year will be made of greatness.
I think @lightweight84, you are absolutely right to question the cash to debt ratio. I think this was one of the reasons that when the ECLS study was first published 2 years ago the share price dropped massively from 1.15 all the way down to 0.5 if i am not wrong. The ECLS publication was huge news but the company just turned round 175k in revenue and had just received a fresh round of funding (credit facility) bringing their debt to 8mio at the time. Investors were very cautious for this exact reason: Will they burn through all their cash and sink like a lead balloon! But i think ONC did a great job in investing the money where it needed to be invested and the seeds sown are starting to spring and expand. I think ONC is in a great position with alot of commercial momentum that will start accelerating (exponentially i hope) . Also having restructured the board, expanded their lab capacity in Dortmund and selling their overheads in the US, they are absolutely conscious of running a Lean Mean Machine whilst continuing to hire quality professionals into the business. But i am confident that these investments are going to pay off with the expected growth in demand. If they hit the 10mio revenue and the share price stands below 2GBP i will tug my tail between my legs, sell my shares and stare at a wall for a while.